Vender R - Search Results

1

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.

Bissonnette R, Maari C, Barber K, Lynde CW, Vender R. Bissonnette R, et al. Among authors: vender r. J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1576-81. doi: 10.1111/jdv.12943. Epub 2015 Jan 20. J Eur Acad Dermatol Venereol. 2015. PMID: 25600828

2

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Papp KA, et al. Lancet. 2008 May 17;371(9625):1675-84. doi: 10.1016/S0140-6736(08)60726-6. Lancet. 2008. PMID: 18486740 Clinical Trial.

3

Treatment of severe facial psoriasis with adalimumab.

Noiles K, Vender R. Noiles K, et al. Among authors: vender r. J Drugs Dermatol. 2008 Dec;7(12):1165-7. J Drugs Dermatol. 2008. PMID: 19137771

4

Efficacy outcomes in patients using alefacept in the AWARE study.

Landells I, Searles G, Bissonnette R, Shear NH, Vender R, Lui H. Landells I, et al. Among authors: vender r. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S122-30. doi: 10.2310/7750.2009.00030. J Cutan Med Surg. 2009. PMID: 20053324 Clinical Trial.

5

An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.

Vender R. Vender R. J Drugs Dermatol. 2011 Apr;10(4):396-402. J Drugs Dermatol. 2011. PMID: 21455550 Clinical Trial.

6

Canadian guidelines for the management of plaque psoriasis: overview.

Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J; Canadian Psoriasis Guidelines Committee. Papp K, et al. J Cutan Med Surg. 2011 Jul-Aug;15(4):210-9. doi: 10.2310/7750.2011.10066. J Cutan Med Surg. 2011. PMID: 21781627

7

Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting.

Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Vender R, et al. Appl Health Econ Health Policy. 2012 Sep 1;10(5):343-53. doi: 10.1007/BF03261868. Appl Health Econ Health Policy. 2012. PMID: 22877226

8

Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.

Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M. Vender R, et al. J Cutan Med Surg. 2012 Nov-Dec;16(6):407-16. doi: 10.1177/120347541201600609. J Cutan Med Surg. 2012. PMID: 23149196 Clinical Trial.

9

One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a Canadian population.

Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M. Vender R, et al. J Cutan Med Surg. 2013 Mar-Apr;17(2):129-38. doi: 10.2310/7750.2012.12036. J Cutan Med Surg. 2013. PMID: 23582167 Clinical Trial.

10

Clinical features of external genital warts.

Lynde C, Vender R, Bourcier M, Bhatia N. Lynde C, et al. Among authors: vender r. J Cutan Med Surg. 2013 Dec;17 Suppl 2:S55-60. J Cutan Med Surg. 2013. PMID: 24388559 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

243 results

Search Page

Filters